

CITATION REPORT

List of articles citing

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

DOI: 10.1016/j.jpba.2008.09.020

Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 1267-81.

Source: <https://exaly.com/paper-pdf/43482178/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
485	[Immunogenicity of therapeutic antibodies]. 2009 , 25, 1070-7		3
484	. 2009 ,		8
483	Challenges in developing antidrug antibody screening assays. <i>Bioanalysis</i> , 2009 , 1, 699-704	2.1	11
482	Assessing specificity for immunogenicity assays. <i>Bioanalysis</i> , 2009 , 1, 611-7	2.1	15
481	Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA. <i>MABs</i> , 2009 , 1, 190-209	6.6	3
480	Conference report: European Bioanalysis Forum. <i>Bioanalysis</i> , 2009 , 1, 273-6	2.1	3
479	Ligand-binding assays: risk of using a platform supported by a single vendor. <i>Bioanalysis</i> , 2009 , 1, 629-362.1		13
478	Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. 2009 , 54, 164-82		197
477	Nonclinical development of biopharmaceuticals. 2009 , 14, 1112-22		22
476	Discovery and development of biopharmaceuticals: current issues. 2009 , 20, 668-72		70
475	Antidrug antibody assay validation: industry survey results. <i>AAPS Journal</i> , 2009 , 11, 133-8	3.7	24
474	Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. 2009 , 61, 977-85		64
473	Immuno-PCR assays for immunogenicity testing. 2009 , 387, 278-82		32
472	Advances in predicting and manipulating the immunogenicity of biotherapeutics and vaccines. 2009 , 23, 231-40		9
471	Development and Validation of Immunogenicity Assays for Preclinical and Clinical Studies. 193-238		1
470	Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum. <i>AAPS Journal</i> , 2010 , 12, 98-106	3.7	9
469	The same genetic defect in three Tunisian families with Bernard Soulier syndrome: a probable founder Stop mutation in GPIb-2010, 89, 75-81		4

468	Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. 2010 , 89 Suppl 1, 75-85		26
467	Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 52, 249-54	3.5	43
466	A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution. <i>Journal of Immunological Methods</i> , 2010 , 352, 161-8	2.5	13
465	Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. <i>Journal of Immunological Methods</i> , 2010 , 357, 10-6	2.5	47
464	Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference. <i>Journal of Immunological Methods</i> , 2010 , 358, 35-45 ^{2.5}		15
463	Immunogenicity: prediction, detection and effective assay development. <i>Bioanalysis</i> , 2010 , 2, 1539-45	2.1	6
462	Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. 2010 , 125, e35-51		150
461	5th Bioanalysis in Clinical Research. <i>Bioanalysis</i> , 2010 , 2, 999-1003	2.1	
460	Antibody Engineering. 2010 ,		4
459	Immunogenicity Assay Development and Validation. 2011 , 487-499		
458	Overcoming immunogenicity associated with the use of biopharmaceuticals. 2011 , 4, 623-31		20
457	Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development. <i>Bioanalysis</i> , 2011 , 3, 535-40	2.1	14
456	. 2011 ,		6
455	Competitive Ligand-Binding Assays for the Detection of Neutralizing Antibodies. 2011 , 175-192		8
454	Confirmatory Immunogenicity Assays. 2011 , 103-117		7
453	Guidance on Immunogenicity Assessment of Biologically Derived Therapeutic Proteins: A European Perspective. 2011 , 37-56		3
452	Cut Points and Performance Characteristics for Anti-Drug Antibody Assays. 2011 , 287-308		7
451	Principles of Risk Assessment and Monitoring of Antibody Responses to Biopharmaceuticals. 2011 , 1-12		2

450	Immunogenicity of Therapeutic Proteins: A Regulatory Perspective. 2011 , 13-35		4
449	Hypersensitivity Reactions to Biopharmaceuticals: Detection and Quantification of Drug-Specific IgE Antibodies. 2011 , 211-231		
448	Standardization and Validation of Immunoassays. 2011 , 233-242		2
447	Standardization and Validation of Cell-Based Assays for the Detection of Neutralizing Anti-Drug Antibodies. 2011 , 243-268		3
446	Antibody Assays in Animal Research. 2011 , 331-341		
445	Immunogenicity of Microbial Digestive Enzymes for Oral Replacement Therapy in Pancreatic Exocrine Insufficiency. 2011 , 343-367		
444	Recommendations for the validation of flow cytometric testing during drug development: II assays. <i>Journal of Immunological Methods</i> , 2011 , 363, 120-34	2.5	80
443	Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. <i>Journal of Immunological Methods</i> , 2011 , 365, 38-49	2.5	76
442	Statistical considerations for calculation of immunogenicity screening assay cut points. <i>Journal of Immunological Methods</i> , 2011 , 373, 200-8	2.5	28
441	Development of a novel radioimmunoassay to detect autoantibodies to amyloid beta peptides in the presence of a cross-reactive therapeutic antibody. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 56, 1029-34	3.5	6
440	Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. 2011 , 16, 345-53		34
439	Refined analysis of antigen-specific antibody responses--a new one-step tool in immunogenicity studies. 2011 , 44, 187-93		1
438	Summary of confirmation cut point discussions. <i>AAPS Journal</i> , 2011 , 13, 227-9	3.7	18
437	Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 55, 878-88	3.5	93
436	Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 286-94	3.5	63
435	Clinical immunogenicity specificity assessments: a platform evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 629-35	3.5	17
434	Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 55, 1041-9	3.5	21
433	A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 55, 1148-56	3.5	19

432	Bioanalytical interferences in immunoassays for antibody biotherapeutics. <i>Bioanalysis</i> , 2011 , 3, 703-6	2.1	16
431	Bioanalytical considerations in the comparability assessment of biotherapeutics. <i>Bioanalysis</i> , 2011 , 3, 613-22	2.1	9
430	Natural antibodies against bone morphogenic proteins and interferons in healthy donors and in patients with infections linked to type-1 cytokine responses. 2011 , 31, 661-9		10
429	Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods. <i>Bioanalysis</i> , 2011 , 3, 883-98	2.1	10
428	Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. <i>Bioanalysis</i> , 2011 , 3, 677-700	2.1	58
427	Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. <i>Clinical Cancer Research</i> , 2011 , 17, 5962-72	12.9	34
426	Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. <i>Bioanalysis</i> , 2011 , 3, 509-21	2.1	31
425	Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. <i>Bioanalysis</i> , 2011 , 3, 523-34	2.1	53
424	Proposal for a new protein therapeutic immunogenicity titer assay cutpoint. <i>Bioanalysis</i> , 2011 , 3, 2627-36.1		3
423	Validation of preclinical pharmacokinetic and immunogenicity assays for an anti-PCSK9 antibody. 2011 , 32, 296-317		2
422	Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic. <i>Bioanalysis</i> , 2012 , 4, 2013-26	2.1	23
421	Strategies to estimate and improve drug tolerance in anti-drug antibody assays. <i>Bioanalysis</i> , 2012 , 4, 1999-2012	2.1	6
420	Development issues: antibody stability, developability, immunogenicity, and comparability. 2012 , 377-595		5
419	Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals. <i>Bioanalysis</i> , 2012 , 4, 2179-90	2.1	7
418	Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. <i>Bioanalysis</i> , 2012 , 4, 2959-70	2.1	13
417	Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. 2012 , 159, 321-6		45
416	Assessment of potential cross-reactivity of human endogenous matrix metalloproteinases with collagenase Clostridium histolyticum antibodies in human sera obtained from patients with Dupuytren® contracture. 2012 , 19, 562-9		16
415	Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. 2012 , 120, 3670-6		39

414	Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics. 2012 , 17, 1282-8		24
413	A survey of applications of biological products for drug interference of immunogenicity assays. 2012 , 29, 3384-92		36
412	Strategic selection and development of immunogenicity binding methods. <i>Bioanalysis</i> , 2012 , 4, 1491-508.	1	9
411	A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. 2012 , 16, R31		19
410	Ligand binding assays in the 21st Century laboratory: platforms. <i>AAPS Journal</i> , 2012 , 14, 113-8	3.7	12
409	Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. <i>AAPS Journal</i> , 2012 , 14, 316-28	3.7	85
408	Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. <i>AAPS Journal</i> , 2012 , 14, 296-302.	3.7	209
407	Development and validation of novel enzyme activity methods to assess inhibition of matrix metalloproteinases (MMPs) in human serum by antibodies against enzyme therapeutics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 70, 408-14	3.5	5
406	Generic anti-drug antibody assay with drug tolerance in serum samples from mice exposed to human antibodies. 2012 , 430, 193-9		13
405	Challenges of immunogenicity assays for vaccines. <i>Bioanalysis</i> , 2012 , 4, 397-406	2.1	9
404	Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. <i>Bioanalysis</i> , 2012 , 4, 2169-77	2.1	27
403	FSDA: A MATLAB toolbox for robust analysis and interactive data exploration. 2012 , 116, 17-32		49
402	Addressing drug effects on cut point determination for an anti-drug antibody assay. <i>Journal of Immunological Methods</i> , 2012 , 384, 152-6	2.5	4
401	Immunogenicity assessment in non-clinical studies. 2012 , 15, 337-47		32
400	Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure. <i>AAPS Journal</i> , 2012 , 14, 843-9	3.7	18
399	Human monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice. <i>PLoS ONE</i> , 2012 , 7, e50954	3.7	11
398	Ligand-Binding Assays. 2012 , 1		
397	Anti-drug antibodies. 2012 , 2, 11		8

396	Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody. <i>Journal of Immunological Methods</i> , 2012 , 375, 258-63	2.5	5
395	Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum. <i>Journal of Immunological Methods</i> , 2012 , 376, 32-45	2.5	15
394	Novel Biopharmaceuticals. 2013 , 97-137		4
393	Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies. 2013 , 441, 174-9		5
392	Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. <i>AAPS Journal</i> , 2013 , 15, 646-58	3.7	50
391	Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. <i>AAPS Journal</i> , 2013 , 15, 551-8	3.7	14
390	Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. <i>AAPS Journal</i> , 2013 , 15, 30-40	3.7	32
389	Comparison of two direct neutralizing assay formats using recombinant follicle-stimulating hormone as agonist. <i>Journal of Immunological Methods</i> , 2013 , 400-401, 87-96	2.5	4
388	Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2). <i>Journal of Immunological Methods</i> , 2013 , 389, 52-60	2.5	15
387	Clinical development of biosimilars: an evolving landscape. <i>Bioanalysis</i> , 2013 , 5, 575-86	2.1	12
386	Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. 2013 , 51, e287-9		30
385	Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 78-79, 39-44	3.5	62
384	False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay. <i>Journal of Immunological Methods</i> , 2013 , 394, 22-31	2.5	23
383	Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. 2013 , 67, 382-91		32
382	Ligand Binding Assays in Drug Development. 2013 , 647-657		
381	Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers. 2013 , 27, 149-58		5
380	The development and validation of an immunoassay for the measurement of anti-thymidine phosphorylase antibodies in mouse and dog sera. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 72, 16-24	3.5	2
379	Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 74, 235-45	3.5	15

378	T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. 2013 , 149, 534-55		180
377	An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 86, 73-81	3.5	10
376	Regarding confirmatory immunogenicity assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 84, 173-6	3.5	3
375	Statistical methods and tool for cut point analysis in immunogenicity assays. <i>Journal of Immunological Methods</i> , 2013 , 389, 79-87	2.5	27
374	Increased sensitivity of SPR assays in plasma through efficient parallel assay optimization. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 78-79, 224-32	3.5	9
373	Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. <i>Journal of Immunological Methods</i> , 2013 , 396, 44-55	2.5	31
372	Novel data analysis methods to overcome cut point challenges and enable comprehensive assessment of antidrug binding activity in confirmatory assays. <i>Journal of Immunological Methods</i> , 2013 , 392, 38-48	2.5	6
371	Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development. <i>Bioanalysis</i> , 2013 , 5, 517-20	2.1	26
370	Adapting dried blood spot sampling for an anti-therapeutic antibody immunogenicity assay. <i>Journal of Immunological Methods</i> , 2013 , 393, 53-60	2.5	2
369	Statistical and bioanalytical considerations for establishing a depletion criterion for specificity testing during immunogenicity assessment of a biotherapeutic. <i>AAPS Journal</i> , 2013 , 15, 1160-7	3.7	6
368	Current regulatory guidelines for immunogenicity assays. 2013 , 6-17		
367	Is the tiered immunogenicity testing of biologics the adequate approach in preclinical development?. <i>Bioanalysis</i> , 2013 , 5, 743-6	2.1	2
366	Universal immunogenicity validation and assessment during early biotherapeutic development to support a green laboratory. <i>Bioanalysis</i> , 2013 , 5, 2495-507	2.1	3
365	Critical reagent stability for immunogenicity assays. 2013 , 92-104		1
364	Good practices for statistical estimation of cut point. 2013 , 50-60		1
363	Immunogenicity Assay Development, Validation and Implementation. 2013 ,		
362	Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. <i>Bioanalysis</i> , 2013 , 5, 1041-55	2.1	27
361	Bioanalysis of Biotherapeutics. 2013 ,		

360	The emergence of obsessive compulsive and compulsive buying symptomatology after acute stress and short-term use of ribavirin: case reports. 2013 , 3, 246-50		2
359	Bioanalytical challenges in the development of biosimilars. 2013 , 62-75		1
358	Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. 2013 , 53, 1240-51		25
357	Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 2013 , 43, 659-64		45
356	Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. <i>Bioanalysis</i> , 2013 , 5, 997-1006	2.1	118
355	Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. <i>Bioanalysis</i> , 2013 , 5, 201-26	2.1	172
354	Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. <i>Bioanalysis</i> , 2013 , 5, 1007-23	2.1	39
353	A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines. <i>MAbs</i> , 2013 , 5, 150-61	6.6	4
352	Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. <i>Bioanalysis</i> , 2013 , 5, 227-44	2.1	38
351	Bioanalysis of antibody-drug conjugates. 2013 , 6-16		
350	Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. 2013 , 121, 1039-48		122
349	Practical considerations for outsourcing ligand binding assays in a regulated environment. 2013 , 96-107		
348	Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. 2013 , 58, 950-7		82
347	Tiered approach to anti-drug antibody testing. 2013 , 74-90		
346	Interview with Dr Bowsher. <i>Bioanalysis</i> , 2013 , 5, 1337-40	2.1	0
345	Drug-tolerant immunogenicity testing. 2013 , 38-48		
344	Perspectives of bioanalysis in drug development. 2013 , 18-34		
343	. 2014 ,		4

342	. 2014,			1
341	Bioanalytical challenges of biosimilars. <i>Bioanalysis</i> , 2014, 6, 349-56	2.1		10
340	Sample size consideration for immunoassay screening cut-point determination. 2014, 24, 535-45			3
339	Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody. <i>Bioanalysis</i> , 2014, 6, 3225-35	2.1		20
338	EBF recommendation for stability testing of anti-drug antibodies; lessons learned from anti-vaccine antibody stability studies. <i>Bioanalysis</i> , 2014, 6, 1409-13	2.1		7
337	Interference in immunoassays to support therapeutic antibody development in preclinical and clinical studies. <i>Bioanalysis</i> , 2014, 6, 1939-51	2.1		22
336	Challenges in bioanalytical assays for biosimilars. <i>Bioanalysis</i> , 2014, 6, 2111-3	2.1		2
335	Free analyte QC concept: a novel approach to prove correct quantification of free therapeutic protein drug/biomarker concentrations. <i>Bioanalysis</i> , 2014, 6, 485-96	2.1		13
334	Stability studies of binding and functional anti-vaccine antibodies. <i>Bioanalysis</i> , 2014, 6, 1385-93	2.1		15
333	2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity). <i>Bioanalysis</i> , 2014, 6, 3355-68	2.1		29
332	Challenges in keeping pace with immunogenicity advances throughout the clinical development of a biological therapeutic. <i>Bioanalysis</i> , 2014, 6, 1953-60	2.1		
331	Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance. <i>Bioanalysis</i> , 2014, 6, 983-92	2.1		15
330	Orthogonal tools to help determine the required selectivity of ligand-binding assays in drug development. <i>Bioanalysis</i> , 2014, 6, 1037-40	2.1		2
329	Mechanisms Underlying the Immunogenicity of Therapeutic Proteins: Risk Assessment and Management Strategies. 2014, 34, 923-930			4
328	A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome. 2014, 134, 1316-22			2
327	Channeling postmarketing patient data into pharmaceutical regulatory systems. 2014, 19, 1897-912			1
326	Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. <i>Bioanalysis</i> , 2014, 6, 1509-23	2.1		21
325	Stability of anti-immunotherapeutic antibodies in frozen human serum samples. <i>Bioanalysis</i> , 2014, 6, 1395-407	2.1		17

324	Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. 2014 , 61, 1135-42		64
323	Protein-based matrix interferences in ligand-binding assays. <i>Bioanalysis</i> , 2014 , 6, 1131-40	2.1	21
322	Immunogenicity/hypersensitivity of biologics. <i>Toxicologic Pathology</i> , 2014 , 42, 293-300	2.1	65
321	A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. <i>AAPS Journal</i> , 2014 , 16, 488-98	3.7	46
320	Immunogenicity of Protein Therapeutics: Risk Assessment and Risk Mitigation. 2014 , 347-368		
319	Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. <i>AAPS Journal</i> , 2014 , 16, 464-77	3.7	28
318	Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. <i>AAPS Journal</i> , 2014 , 16, 658-73	3.7	187
317	A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 88, 27-35	3.5	4
316	Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. <i>Journal of Immunological Methods</i> , 2014 , 408, 1-12	2.5	44
315	Bioanalytical Methods and Immunogenicity Assays. 2014 , 207-242		
314	Immunological Issues with Nanomedicines: Immunogenicity, Hypersensitivity, Accelerated Clearance and Immune Suppression. 2014 , 45-73		3
313	Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN- α 1a. <i>Bioanalysis</i> , 2015 , 7, 2801-11	2.1	6
312	Antidrug Antibodies: B Cell Immunity Against Therapy. 2015 , 82, 184-90		6
311	Immunogenicity considerations. 2015 , 23-66		
310	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity). <i>Bioanalysis</i> , 2015 , 7, 3107-24	2.1	51
309	Considerations on Immunogenicity. 2015 , 457-467		
308	Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. <i>AAPS Journal</i> , 2015 , 17, 1144-56	3.7	25
307	Comparative immunogenicity assessment: a critical consideration for biosimilar development. <i>Bioanalysis</i> , 2015 , 7, 373-81	2.1	20

306	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. 2015 , 5, 598-609		65
305	Blockade of interferon- γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. 2015 , 67, 2713-22		46
304	Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. 2015 , 181, 385-400		62
303	An ex vivo potency assay to assess active drug levels of a GLP-1 agonistic peptide during preclinical safety studies. <i>Bioanalysis</i> , 2015 , 7, 3063-72	2.1	4
302	Novel Methods for Addressing Immunogenicity of Therapeutic Enzymes. 2015 , 63-77		1
301	Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples. <i>Journal of Immunological Methods</i> , 2015 , 416, 124-36	2.5	15
300	Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay. 2015 , 25, 269-79		17
299	Infliximab drug and antibody levels in patients with dermatological conditions. 2015 , 37, 320-6		3
298	Isolation of high-affinity, neutralizing anti-idiotypic antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses. <i>Journal of Immunological Methods</i> , 2015 , 416, 49-58	2.5	13
297	A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective. <i>Journal of Immunological Methods</i> , 2015 , 417, 1-9	2.5	26
296	Statistical approaches for the determination of cut points in anti-drug antibody bioassays. <i>Journal of Immunological Methods</i> , 2015 , 418, 84-100	2.5	14
295	Managing unwanted immunogenicity of biologicals. 2015 , 14, 569-74		40
294	Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN- α 1a and PEG-IFN- α 2a in naive patients. <i>Bioanalysis</i> , 2015 , 7, 1093-106	2.1	25
293	Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity. <i>MABs</i> , 2015 , 7, 662-71	6.6	67
292	Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. 2015 , 43, 298-306		93
291	Sponsor relationships, analyte stability in ligand-binding assays and critical reagent management: a bioanalytical CRO perspective. <i>Bioanalysis</i> , 2015 , 7, 1337-46	2.1	3
290	Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation. <i>Journal of Immunological Methods</i> , 2015 , 425, 88-96	2.5	1
289	Feasibility of immuno-PCR technology platforms as an ultrasensitive tool for the detection of anti-drug antibodies. <i>Bioanalysis</i> , 2015 , 7, 285-94	2.1	14

288	Evaluation of the immunogenicity of the synthetic β -melanocyte-stimulating hormone (β MSH) analogue afamelanotide ([Nle ⁴ -D-Phe ⁷]- β MSH, Scenesse [®]) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti- β MSH antibodies. 2015 , 28, 103-13			7
287	The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. 2015 , 7, 269ra1			66
286	Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. 2015 , 45, 1393-402			46
285	Development of an ELISA for the Pharmacokinetic Evaluation of a Murine Anti CD66 Monoclonal Antibody in Human Serum. 2015 , 36, 579-96			
284	Insights on the immunogenicity of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1565-8	2.1		13
283	Recommendations for the development and validation of confirmatory anti-drug antibody assays. <i>Bioanalysis</i> , 2015 , 7, 1619-31	2.1		7
282	Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13). 2015 , 11 Suppl 1, S33-41			24
281	A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. <i>Journal of Immunological Methods</i> , 2015 , 426, 62-9	2.5		41
280	Biobetters. 2015 ,			1
279	Epitope characterization of the ADA response directed against a targeted immunocytokine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 296-304	3.5		8
278	Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults. 2015 , 59, 4919-29			23
277	Non-normal random effects models for immunogenicity assay cut point determination. 2015 , 25, 295-306			7
276	Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. <i>AAPS Journal</i> , 2015 , 17, 35-43	3.7		49
275	Pharmacokinetics of Recombinant Soluble Human Thrombomodulin in Subjects with Normal and Various Impaired Renal Function. 2016 , 5,			1
274	. 2016 ,			4
273	Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. 2016 , 2016, 2342187			37
272	Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance. 2016 , 2016, 5069678			18
271	Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy. 2016 , 2016, 9248061			3

270	Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development. 2016 , 2016, 2618575		11
269	Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation. 2016 , 2016, 7682472		21
268	Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. <i>PLoS ONE</i> , 2016 , 11, e0159328	3.7	59
267	Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients. <i>PLoS ONE</i> , 2016 , 11, e0164230	3.7	14
266	Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance. 2016 , 2016, 3072586		40
265	Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. 2016 , 56, 1516-1527		29
264	GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 3238-48	12.9	19
263	Bioanalytical Development. 2016 , 459-477		
262	Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. 2016 , 75, 1693-6		56
261	An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox. <i>Journal of Immunological Methods</i> , 2016 , 435, 68-76	2.5	9
260	Physicochemical characterization of biopharmaceuticals. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 130, 366-389	3.5	40
259	Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. 2016 , 150, 799-810		274
258	The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders. 2016 , 39, 499-512		14
257	An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies. <i>Bioanalysis</i> , 2016 , 8, 2157-68	2.1	4
256	Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I. <i>Bioanalysis</i> , 2016 , 8, 2135-45	2.1	6
255	BAY 81-8973, a full-length recombinant factor VIII: Human heat shock protein 70 improves the manufacturing process without affecting clinical safety. 2016 , 127, 111-115		5
254	A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 128, 166-173	3.5	4
253	Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value. 2016 , 38, 1142-8		6

252	Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics. <i>AAPS Journal</i> , 2016 , 18, 1335-1350	3.7	33
251	2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies). <i>Bioanalysis</i> , 2016 , 8, 2457-2474	2.1	24
250	Development, validation, and application of ELISA for detection of anti-HD105 antibodies in pre-clinical safety evaluation using monkeys. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 131, 309-315	3.5	1
249	Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. 2016 , 186, 364-372		22
248	Bioanalytical Strategies Enabling Successful ADC Translation. 2016 , 177-205		
247	Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model. 2016 , 244, 1-13		35
246	Response to: Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required by Moots et al. 2016 , 75, e25		5
245	Assessing the Immunogenicity of Biopharmaceuticals. 2016 , 30, 195-206		75
244	Clinical Assays for Biological Macromolecules. 2016 , 263-294		
243	Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. <i>Journal of Immunological Methods</i> , 2016 , 430, 1-9	2.5	10
242	Diagnostic parameters of serological ELISA for invasive amoebiasis, using antigens preserved without enzymatic inhibitors. 2016 , 161, 48-53		9
241	Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies. <i>Journal of Immunological Methods</i> , 2016 , 431, 45-51	2.5	17
240	Pre-existing Antibody: Biotherapeutic Modality-Based Review. <i>AAPS Journal</i> , 2016 , 18, 311-20	3.7	45
239	A subcutaneous cellular implant for passive immunization against amyloid- β reduces brain amyloid and tau pathologies. 2016 , 139, 1587-604		23
238	Indirect assessment of neutralizing anti-drug antibodies utilizing pharmacokinetic assay data. <i>Journal of Immunological Methods</i> , 2016 , 429, 28-38	2.5	
237	Immunogenicity assay cut point determination using nonparametric tolerance limit. <i>Journal of Immunological Methods</i> , 2017 , 442, 29-34	2.5	6
236	Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1815-1825	3.8	10
235	A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. 2017 , 76, 526-533		56

234	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. 2017 , 23, 1909-1917		17
233	Assessment of the immunogenicity of gonadotrophins during controlled ovarian stimulation. 2017 , 78, e12675		5
232	A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay. <i>Journal of Immunological Methods</i> , 2017 , 446, 30-36	2.5	11
231	Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice. 2017 , 54, 685-693		1
230	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. 2017 , 31, 223-237		27
229	Regulated Bioanalysis: Fundamentals and Practice. 2017 ,		3
228	Understanding Bioanalysis Regulations. 2017 , 15-38		2
227	Monitoring Quality of Critical Reagents Used in Ligand Binding Assays with Liquid Chromatography Mass Spectrometry (LC-MS). 2017 , 107-128		3
226	Bridging immunogenicity assays for IgG4 therapeutics: mitigating interference from Fc-Fc interactions. <i>Bioanalysis</i> , 2017 , 9, 707-717	2.1	2
225	Development and Characterization of a Neutralizing Anti-idiotypic Antibody Against Mirvetuximab for Analysis of Clinical Samples. <i>AAPS Journal</i> , 2017 , 19, 1223-1234	3.7	1
224	Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation. <i>Bioanalysis</i> , 2017 , 9, 849-859	2.1	7
223	Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome. <i>Journal of Immunological Methods</i> , 2017 , 440, 41-51	2.5	11
222	Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint. <i>AAPS Journal</i> , 2017 , 19, 313-319	3.7	6
221	Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody. <i>Journal of Immunological Methods</i> , 2017 , 441, 15-23	2.5	9
220	Method establishment for discerned immunogenicity assessment of a recombinant glycoprotein containing nonhuman sialic acid Neu5Gc residues. <i>Bioanalysis</i> , 2017 , 9, 1385-1393	2.1	2
219	Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies. <i>AAPS Journal</i> , 2017 , 19, 1564-1575	3.7	23
218	Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response. <i>Bioanalysis</i> , 2017 , 9, 1849-1858	2.1	7
217	Recombinant humanized anti-vascular endothelial growth factor monoclonal antibody efficiently suppresses laser-induced choroidal neovascularization in rhesus monkeys. 2017 , 109, 624-630		4

216	Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. 2017 , 35, 5883-5889		6
215	Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach. <i>Bioanalysis</i> , 2017 , 9, 1395-1406	2.1	9
214	Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study. 2017 , 19, 516-526		18
213	Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points. <i>AAPS Journal</i> , 2017 , 19, 1487-1498	3.7	37
212	Development of NanoLuc bridging immunoassay for detection of anti-drug antibodies. <i>Journal of Immunological Methods</i> , 2017 , 450, 17-26	2.5	21
211	Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space. <i>AAPS Journal</i> , 2017 , 19, 1656-1668	3.7	18
210	Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. 2017 , 13, 707-718		96
209	Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development. <i>AAPS Journal</i> , 2017 , 19, 1576-1586	3.7	9
208	Strategy to detect pre-existing immunity to AAV gene therapy. <i>Gene Therapy</i> , 2017 , 24, 768-778	4	45
207	Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. 2017 , 8, 305		6
206	Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story. <i>PLoS ONE</i> , 2017 , 12, e0186211	3.7	26
205	Emerging Bioanalytical Methods for the Bioanalysis of Biotherapeutics. 2017 , 180-197		
204	Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects. 2018 , 32, 83-89		5
203	Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles. <i>Bioanalysis</i> , 2018 , 10, 197-204	2.1	9
202	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. 2018 , 24, 601-606		42
201	Immunogenicity of biologic therapies: causes and consequences. 2018 , 14, 513-523		32
200	Generic Anti-PEG Antibody Assay on ProterixBio® (Formerly BioScale) ViBE Platform Shows Poor Reproducibility. <i>AAPS Journal</i> , 2018 , 20, 65	3.7	3
199	Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection. <i>Bioanalysis</i> , 2018 , 10, 803-814	2.1	12

198	Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies. 2018 , 33, 125-132		
197	Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. 2018 , 192, 348-365		40
196	Comparative assessment of pharmacokinetics, and pharmacodynamics between RTX833a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. 2018 , 81, 515-527		25
195	Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. 2018 , 20, 160-170		10
194	Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment. <i>AAPS Journal</i> , 2017 , 20, 25	3.7	6
193	Immunogenicity considerations for antibody-drug conjugates: a focus on neutralizing antibody assays. <i>Bioanalysis</i> , 2018 , 10, 65-70	2.1	4
192	Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan. <i>Bioanalysis</i> , 2018 , 10, 95-105	2.1	22
191	Fluorescence Sandwich Assays for Protein Detection. 2018 , 29-45		1
190	Biosensors Based on Sandwich Assays. 2018 ,		4
189	IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution. 2018 , 73, 2172-2181		6
188	Application of automated liquid handling in ligand-binding assay-based bioanalytical method development: the practical considerations. <i>Bioanalysis</i> , 2018 , 10, 425-430	2.1	5
187	State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015. 2018 , 32, e130-e132		5
186	Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. <i>Journal of Immunological Methods</i> , 2018 , 452, 73-77	2.5	12
185	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. 2018 , 77, 165-174		120
184	Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study. 2018 , 20, 49-58		14
183	Immunogenicity of branched polyethylene glycol modified interferon alpha. 2018 , 40, 35-42		1
182	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. 2018 , 4, e000757		18
181	Perspectives on potentiating immunocapture-LC-MS for the bioanalysis of biotherapeutics and biomarkers. <i>Bioanalysis</i> , 2018 , 10, 1679-1690	2.1	8

180	Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. 2018 , 13, 55-64		12
179	Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessments. <i>Journal of Immunological Methods</i> , 2018 , 463, 105-111	2.5	6
178	2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA/cell-based assays: immunogenicity, biomarkers and PK assays). <i>Bioanalysis</i> , 2018 , 10, 1973-2001	2.1	27
177	Validation of an Immunoassay for Anti-thymidine Phosphorylase Antibodies in Patients with MNGIE Treated with Enzyme Replacement Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018 , 11, 1-8	6.4	5
176	Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study. 2018 , 197, 68-76		21
175	Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. 2018 , 483, 308-314		6
174	Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2GMOE-Modified Antisense Oligonucleotide. 2018 , 164, 613-626		18
173	Development and validation of a functional cell-based neutralizing antibody assay for ipilimumab. <i>Bioanalysis</i> , 2018 , 10, 1273-1287	2.1	3
172	Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy. <i>Bioanalysis</i> , 2018 , 10, 1221-1228	2.1	3
171	Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. <i>Antibodies</i> , 2018 , 7,	7	8
170	Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. 2018 , 179, 169-179		9
169	Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia. <i>AAPS Open</i> , 2018 , 4,	2.2	4
168	Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing. <i>Journal of Immunological Methods</i> , 2018 , 462, 34-41	2.5	5
167	Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics. <i>Bioanalysis</i> , 2018 , 10, 1289-1306	2.1	3
166	A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2270-2279	3.8	18
165	Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. 2018 , 48, 507-522		16
164	Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018 , 10, 105-112	6.4	127
163	Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody. <i>Journal of Immunological Methods</i> , 2019 , 474, 112642	2.5	2

162	Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. <i>MAbs</i> , 2019 , 11, 1443-1451	6.6	36
161	Evaluation of in-study cut points to enable appropriate interpretation of clinical immunogenicity results. <i>Bioanalysis</i> , 2019 , 11, 1539-1541	2.1	4
160	Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift. <i>AAPS Journal</i> , 2019 , 21, 89	3.7	9
159	Collagen type-V is a danger signal associated with primary graft dysfunction in lung transplantation. 2019 , 56, 101224		7
158	A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance. <i>AAPS Journal</i> , 2019 , 21, 92	3.7	7
157	Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study. <i>Bioanalysis</i> , 2019 , 11, 509-524	2.1	2
156	Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH. <i>Bioanalysis</i> , 2019 , 11, 1569-1580	2.1	2
155	Current challenges in assessing immunogenicity. <i>Bioanalysis</i> , 2019 , 11, 1543-1546	2.1	2
154	Assessing the long-term stability of anti-drug antibodies in method validation: what is the added value?. <i>Bioanalysis</i> , 2019 , 11, 1899-1903	2.1	1
153	Use of Ella to facilitate drug quantification and antidrug antibody detection in preclinical studies. <i>Bioanalysis</i> , 2019 , 11, 153-164	2.1	3
152	Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies. 2019 , 33, 571-579		6
151	Perspectives on exploring hybrid LBA/LC-MS approach for clinical immunogenicity testing. <i>Bioanalysis</i> , 2019 , 11, 1605-1617	2.1	5
150	Generic immune complex assay for detection of murine anti-drug-antibodies in complex with human IgG. 2019 , 60, 42-48		2
149	Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis. <i>AAPS Journal</i> , 2019 , 21, 76	3.7	1
148	Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials. <i>Bioanalysis</i> , 2019 , 11, 1555-1568	2.1	14
147	Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease. 2019 , 74, e824		3
146	Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers. 2019 , 63,		24
145	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. 2019 , 21, 130		10

144	Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points. <i>AAPS Journal</i> , 2019 , 21, 71	3-7	2
143	Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics. 2019 , 33, 275-284		27
142	Evaluation of potential biotin interference in immunogenicity testing. <i>Bioanalysis</i> , 2019 , 11, 1547-1554	2.1	2
141	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. 2019 , 33, 1733-1741		12
140	Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease. 2019 , 120, 54-61		1
139	Immunogenicity of Therapeutic Proteins. 2019 , 139-150		2
138	Report on the AAPS Immunogenicity Guidance Forum. <i>AAPS Journal</i> , 2019 , 21, 55	3-7	7
137	PF-06881893 (Nivestym [®]), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. 2019 , 33, 207-220		4
136	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. <i>PLoS ONE</i> , 2019 , 14, e0212023	3-7	26
135	Biological Significance of Anti-GH Antibodies in Children Treated with rhGH. 2019 , 91, 17-24		4
134	Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. <i>AAPS Journal</i> , 2019 , 21, 46	3-7	6
133	Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. 2019 , 25, 1532-1540		11
132	Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. 2019 , 19, 122		2
131	EBF recommendation on practical management of critical reagents for antidrug antibody ligand-binding assays. <i>Bioanalysis</i> , 2019 , 11, 1787-1798	2.1	8
130	Bioanalysis of adeno-associated virus gene therapy therapeutics: regulatory expectations. <i>Bioanalysis</i> , 2019 , 11, 2011-2024	2.1	6
129	Approaches to improve drug tolerance and target tolerance in the assessment of neutralizing anti-drug antibodies. <i>Bioanalysis</i> , 2019 , 11, 2061-2074	2.1	2
128	Analysis of regulatory guidance on antidrug antibody testing for therapeutic protein products. <i>Bioanalysis</i> , 2019 , 11, 2283-2296	2.1	2
127	Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus. 2019 , 62, 373-386		8

126	Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. 2019 , 38, 195-205		15
125	Approaches to Resolve False Reporting in Neutralizing Antibody Assays Caused by Reagent Leaching from Affinity Capture Elution Solid Phase. <i>AAPS Journal</i> , 2018 , 21, 4	3-7	3
124	Prediction of natalizumab anti-drug antibodies persistency. 2019 , 25, 392-398		6
123	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. 2020 , 47, 539-547		12
122	Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences. 2020 , 109, 30-43		4
121	Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics. 2020 , 34, 39-54		7
120	Methods and applications of percentile estimation. 2020 , 30, 267-276		1
119	A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains. <i>Journal of Immunological Methods</i> , 2020 , 477, 112688	2-5	5
118	Establishment of a Highly Sensitive Assay for Detection of Hepatitis E Virus-Specific Immunoglobulins. 2020 , 58,		3
117	Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays. <i>AAPS Journal</i> , 2020 , 22, 24	3-7	10
116	Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. <i>Journal of Immunological Methods</i> , 2020 , 479, 112736	2-5	6
115	Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. <i>AAPS Journal</i> , 2019 , 22, 7	3-7	6
114	Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?. <i>AAPS Journal</i> , 2020 , 22, 127	3-7	2
113	Design and Evaluation of a Multiplexed Assay to Assess Human Immunogenicity Against Humira®. <i>AAPS Journal</i> , 2020 , 22, 104	3-7	1
112	Overcoming multimeric target interference in a bridging immunogenicity assay with soluble target receptor, target immunodepletion and mild acidic assay pH. <i>Bioanalysis</i> , 2020 , 12, 1071-1085	2-1	1
111	Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. 2020 , 154-155, 163-175		103
110	How ADA methodology informs SARS-CoV-2 assay development. <i>Bioanalysis</i> , 2020 , 12, 1275-1277	2-1	
109	Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?. <i>Bioanalysis</i> , 2020 , 12, 1325-1336	2-1	1

108	Strategies to develop highly drug-tolerant cell-based neutralizing antibody assay: neutralizing antidrug antibodies extraction and drug depletion. <i>Bioanalysis</i> , 2020 , 12, 1279-1293	2.1	0
107	Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 1101-1113	5.1	8
106	Drug Removal Strategies in Competitive Ligand Binding Neutralizing Antibody (NAb) Assays: Highly Drug-Tolerant Methods and Interpreting Immunogenicity Data. <i>AAPS Journal</i> , 2020 , 22, 112	3.7	1
105	Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. 2020 , 13, 1756284820965790		3
104	Current Considerations for Immunoglobulin Isotype Characterization of Antibody Response against Biotherapeutics. <i>AAPS Journal</i> , 2020 , 22, 144	3.7	3
103	Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies. 2020 , 130, 215-224		0
102	Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. 2020 , 49, 361-370		
101	Development of a Highly Specific Anti-drug Antibody Assay in Support of a Nanoparticle-based Therapeutic. <i>AAPS Journal</i> , 2020 , 22, 81	3.7	
100	MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. 2020 , 12,		7
99	Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody. <i>AAPS Journal</i> , 2020 , 22, 60	3.7	2
98	Development of a Cell-Based Assay for the Detection of Neutralizing Antibodies to PF-06730512 Using Homogenous Time-Resolved Fluorescence. <i>AAPS Journal</i> , 2020 , 22, 56	3.7	
97	A new method for identification of outliers in immunogenicity assay cut point data. <i>Journal of Immunological Methods</i> , 2020 , 484-485, 112817	2.5	4
96	T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. <i>Frontiers in Immunology</i> , 2020 , 11, 1301	8.4	28
95	High ionic strength dissociation assay (HISDA) for high drug tolerant immunogenicity testing. <i>Bioanalysis</i> , 2020 , 12, 857-866	2.1	0
94	Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?. <i>Bioanalysis</i> , 2020 , 12, 1021-1031	2.1	4
93	Confirmatory cut point has limited ability to make accurate classifications in immunogenicity assays. <i>Bioanalysis</i> , 2020 , 12, 245-256	2.1	1
92	Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants. 2020 , 16, 1327-1337		
91	Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. <i>Journal of Immunological Methods</i> , 2020 , 479, 112764 ⁵		4

90	Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients. <i>Clinical and Translational Science</i> , 2020 , 13, 547-554	4.9	3
89	Site-specific PEGylation of interferon beta-1b. 2020 , 317-349		2
88	Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies. <i>AAPS Journal</i> , 2020 , 22, 36	3.7	1
87	Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine. 2020 , 40, 978-989		6
86	Novel bioanalytical method for the characterization of the immune response directed against a bispecific F(ab) fragment. <i>Bioanalysis</i> , 2020 , 12, 509-517	2.1	3
85	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?. <i>Frontiers in Immunology</i> , 2020 , 11, 589	8.4	10
84	Formation and Glomerular Deposition of Immune Complexes in Mice Administered Human Antibodies: Evaluation of Dose, Frequency, and Biomarkers. <i>Toxicologic Pathology</i> , 2020 , 48, 570-585	2.1	
83	Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates. <i>Gene Therapy</i> , 2021 ,	4	6
82	An integrated approach for characterizing immunogenic responses toward a bispecific antibody. <i>MABs</i> , 2021 , 13, 1944017	6.6	5
81	Full validation of an ELISA for quantification of antibodies against <i>Haemophilus influenzae</i> type b capsular polysaccharide. <i>Journal of Applied Biotechnology & Bioengineering</i> , 2021 , 8, 24-31	1.7	
80	Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeutics. <i>Bioanalysis</i> , 2021 , 13, 239-252	2.1	3
79	Assay concept for detecting anti-drug IgM in human serum samples by using a novel recombinant human IgM positive control. <i>Bioanalysis</i> , 2021 , 13, 253-263	2.1	0
78	2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (- Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guidelines, Gene & Cell Therapy and Vaccine Assays). <i>Bioanalysis</i> , 2021 ,	2.1	8
77	2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (- Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell	2.1	7
76	Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1049-1059	6.2	4
75	ELISA validation approach for the detection of anti-saccharomyces cerevisiae antibodies in patients treated with biopharmaceutical heberprot-P. <i>Journal of Analytical & Pharmaceutical Research</i> , 2021 , 10, 50-56	0.4	
74	Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study. <i>PLoS ONE</i> , 2021 , 16, e0249049	2.7	3
73	A strategic approach to nonclinical immunogenicity assessment: a recommendation from the European Bioanalysis Forum. <i>Bioanalysis</i> , 2021 , 13, 537-549	2.1	3

72	Statistical methods of screening cut point determination in immunogenicity studies. <i>Bioanalysis</i> , 2021 , 13, 551-563	2.1	0
71	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4323-4333	3.8	6
70	Comparing singlet and duplicate immunogenicity assay in human plasma for pembrolizumab using Gyrolab. <i>Bioanalysis</i> , 2021 , 13, 891-900	2.1	1
69	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 4511-4520	12.0	10
68	Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant human granulocyte colony-stimulating factor, in rat and monkey models. <i>Scientific Reports</i> , 2021 , 11, 12004	4.9	0
67	First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. <i>Clinical and Translational Science</i> , 2021 , 14, 1590-1599	4.9	1
66	Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement. <i>Plastic and Reconstructive Surgery</i> , 2021 , 148, 287-298	2.7	
65	Development of a novel capillary electrophoresis-based approach for detection of anti-drug antibody responses. <i>Journal of Immunological Methods</i> , 2021 , 494, 113047	2.5	1
64	Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study. <i>Digestion</i> , 2021 , 102, 929-937	3.6	0
63	Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective. <i>Antibodies</i> , 2021 , 10,	7	1
62	Novel methodology comparing two assay formats for the assessment of immunogenicity from clinical trial samples. <i>Bioanalysis</i> , 2021 ,	2.1	
61	Feasibility of singlicate-based analysis in bridging ADA assay on Meso-Scale Discovery platform: comparison with duplicate analysis. <i>Bioanalysis</i> , 2021 , 13, 1123-1134	2.1	0
60	Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain. <i>Scientific Reports</i> , 2021 , 11, 15467	4.9	0
59	Validation of high-throughput, semiquantitative solid-phase SARS-CoV-2 serology assays in serum and dried blood spot matrices. <i>Bioanalysis</i> , 2021 , 13, 1183-1193	2.1	1
58	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. <i>Frontiers in Immunology</i> , 2021 , 12, 709994	8.4	0
57	Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays. <i>AAPS Journal</i> , 2021 , 23, 108	3.7	4
56	Secondary failure: immune responses to approved protein therapeutics. <i>Trends in Molecular Medicine</i> , 2021 , 27, 1074-1083	11.5	0
55	A New Electrochemiluminescence-Based Multiplex Assay for the Assessment of Human Antibody Responses to Bordetella pertussis Vaccines. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 2539-2561	6.2	1

54	Calibration-free concentration analysis for quantification of anti-drug specific antibodies in polyclonal positive control antibodies and in clinical samples. <i>Journal of Immunological Methods</i> , 2021 , 497, 113002	2.5	0
53	Immunogenicity Testing Using Flow Cytometry. 205-223		1
52	Regulatory Compliance and Method Validation. 243-266		1
51	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348	11.6	13
50	Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015 , 53, 1015-27	2	50
49	Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry. <i>Blood Advances</i> , 2021 , 5, 4969-4979	7.8	2
48	Improvement of stability and in vivo antioxidant effect of human glutathione peroxidase mutant by PEGylation. <i>International Journal of Pharmaceutics</i> , 2021 , 609, 121152	6.5	
47	Human Anti-antibody Response. 2010 , 507-515		
46	Immunogenicity Assay Development and Validation. 2011 , 521-534		
45	Toxicology and Adverse Drug Reactions. 157-214		
44	References. 2012 , 459-595		1
43	Monoclonal Antibodies. <i>Cancer Drug Discovery and Development</i> , 2014 , 585-624	0.3	
42	Considerations for the Preclinical Safety Evaluation of Biopharmaceuticals?. 2015 ,		
41	Regulatory considerations. 2016 , 8-21		
40	Cut point computation in immunogenicity assays: a tutorial. 2016 , 84-108		
39	A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin [®] (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers. <i>Drug Development and Registration</i> , 2019 , 8, 91-100	0.6	
38	Development of an anti-drug antibody assay to detect anti-drug antibodies to protein and PEG in a PEGylated molecule. <i>Bioanalysis</i> , 2020 , 12, 1671-1679	2.1	
37	Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. <i>MAbs</i> , 2021 , 13, 1994690	6.6	0

36	The method history report: an adaptable tool for communicating immunogenicity assay development and validation. <i>Bioanalysis</i> , 2020 , 12, 1597-1605	2.1	
35	A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). <i>AAPS Open</i> , 2021 , 7,	2.2	0
34	A comparative multi-tiered immunogenicity assessment of biosimilar pegylated filgrastim: validation of methods for clinical assessment of INTP5. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-10	5.4	
33	Anti-drug Antibody Validation Testing and Reporting Harmonization. <i>AAPS Journal</i> , 2021 , 24, 4	3.7	1
32	A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab. <i>Clinical and Translational Science</i> , 2021 ,	4.9	4
31	Confirmatory detection of neutralizing antibodies to AAV gene therapy using a cell-based transduction inhibition assay.. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022 , 24, 222-229	6.4	0
30	Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12674	5.1	
29	Approaches for the detection and analysis of anti-drug antibodies to biopharmaceuticals: A review.. <i>Journal of Separation Science</i> , 2022 ,	3.4	
28	A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody. <i>AAPS Open</i> , 2021 , 7,	2.2	0
27	A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.. <i>Human Reproduction</i> , 2022 ,	5.7	0
26	Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays. <i>AAPS Open</i> , 2022 , 8,	2.2	
25	2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness[- Recommendations on Gene Therapy, Cell Therapy, Virus-like Particle Immunogenicity, and Biologics Development. <i>Journal of Pharmaceutical Sciences</i> , 2022 , 111, 1-12	2.1	1
24	Seroprevalence to adeno-associated virus type 6 in people with hemophilia B from a UK adult cohort. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6,	5.1	1
23	Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium. <i>AAPS Journal</i> , 2022 , 24,	3.7	
22	Pre-existing Reactivity to an IgG4 Fc-Epitope: Characterization and Mitigation of Interference in a Bridging Anti-drug Antibody Assay. <i>AAPS Journal</i> , 2022 , 24,	3.7	
21	A Randomized, Double-Blind, Parallel Controlled, Single-Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects. <i>Clinical Pharmacology in Drug Development</i> ,	2.3	0
20	Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials. <i>Gene Therapy</i> ,	4	0
19	Gene Therapy and Cell Therapy: Bioanalytical Challenges and Practical Solutions. 2022 , 103-130		

- 18 Statistical Aspects of Bioanalytical Testing. **2022**, 239-276
- 17 Regulatory Aspects for Assay Development, Validation, and Sample Analysis. **2022**, 327-353
- 16 Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs). **2022**, 24,
- 15 An Introduction to Bioanalysis of Monoclonal Antibodies. **2022**, 19-47 ○
- 14 Anti-drug Antibody Sample Testing and Reporting Harmonization. **2022**, 24, ○
- 13 Affinity Capture Elution (ACE) ELISA Method Development and Validation for Novel RPH-104 Drug Immunogenicity Evaluation. **2022**, 10, 2750 ○
- 12 An electrochemiluminescence assay for quantification of Denileukin Diftitox and its anti-drug antibodies in rat serum. **2023**, 119, 107239 ○
- 11 Fit-for-purpose validation of a drug-tolerant immunogenicity assay for a human mAb drug in animal safety studies. **2023**, 512, 113406 ○
- 10 Immunogenicity Considerations for Therapeutic Modalities Used in Rare Diseases. **2022**, 62, 1
- 9 A method for detection of anti-drug antibodies to a biotherapeutic (CSL112) with endogenous counterpart (apolipoprotein A-I) using a novel sample pre-treatment electrochemiluminescence assay. **2023**, 513, 113411 ○
- 8 Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal. **2023**, 25, ○
- 7 Aptamer-based sample purification for mass spectrometric quantification of trastuzumab in human serum. **2023**, 257, 124349 ○
- 6 The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation. **2023**, 116, 109704 ○
- 5 Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer® Disease. ○
- 4 Immunogenicity of Therapeutic Proteins. **2023**, 251-273 ○
- 3 Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII. **2023**, ○
- 2 Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human Serum. **2023**, 25, ○
- 1 Comparability of the Reference Drug Pulmozim and a Similar Drug Tigerase in Terms of their Pharmacodynamic, Toxicological and Pharmacokinetic Properties. **2023**, 19, 47-60 ○

